{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-424755","form_type":"8-K","ticker":"EYPT","cik":"0001314102","company_name":"EyePoint, Inc.","filed_at":"2026-10-19T13:22:16+00:00","discovered_at":"2026-10-19T13:23:00.259155+00:00","generated_at":"2026-10-19T13:23:06.353747+00:00","sec_items":["2.02","2.05","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"EyePoint's DURAVYU misses Phase 3 LUCIA primary endpoint; 53% workforce cut, wet AMD trials halted","bullets":["Phase 3 LUCIA study of DURAVYU in wet AMD did not meet the primary endpoint of non-inferiority, though vision improved and key secondary endpoints were met.","EyePoint will conclude both pivotal Phase 3 wet AMD trials early, without completing year two, and cut approximately 53% of positions, mostly in Q4 2026, finishing in 1H 2027.","Restructuring carries about $9M in severance and related charges but is expected to generate roughly $30M in annualized savings.","Company estimates ~$118M in cash, cash equivalents and short-term investments as of September 30, 2026; figures are preliminary and unaudited.","Resources now focus on DURAVYU in DME, with Phase 3 COMO and CAPRI (551 patients) topline data expected in Q4 2027; VERONA Phase 2 showed >70% supplement-free at six months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-424755","json":"https://secwatch.observer/filing/0001193125-26-424755.json","markdown":"https://secwatch.observer/filing/0001193125-26-424755.md","text":"https://secwatch.observer/filing/0001193125-26-424755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/0001193125-26-424755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1314102/000119312526424755/eypt-20261017.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-19T13:23:06.353747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}